Advance in therapy Parkinson's disease
Roth, J.; Růzicka, E.; Kanovský, P.
Vnitrni Lekarstvi 46(11): 811-816
2000
ISSN/ISBN: 0042-773X PMID: 15637899 Document Number: 514397
Document emailed within 1 workday
Related Documents
Jankovic, J. 2001: Parkinson's disease therapy: treatment of early and late disease Chinese Medical Journal 114(3): 227-234Jiménez Jiménez, F.J.; Ladero Quesada, J.M. 1990: An experimental model of Parkinson disease caused by a neurotoxin: implications in the clinical aspects and the etiology of Parkinson disease Medicina Clinica 94(15): 585-595
Tanasanvimon, S.; Ayuthaya, N.I.N.; Phanthumchinda, K. 2007: Modified Parkinson's Disease Sleep Scale (MPDSS) in Thai Parkinson's disease patients Journal of the Medical Association of Thailand 90(11): 2277-2283
Hattori, N. 2004: Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease Rinsho Shinkeigaku 44(4-5): 241-262
Bhat, V.; Weiner, W.J. 2005: Parkinson's disease. Diagnosis and the initiation of therapy Minerva Medica 96(3): 145-154
Chase, T.N.; Baronti, F.; Fabbrini, G.; Heuser, I.J.; Juncos, J.L.; Mouradian, M.M. 1989: Rationale for continuous dopaminomimetic therapy of Parkinson's disease Neurology 39(11 Suppl 2: 7
Möller, J.C.; Sautter, J.; Kupsch, A. 1996: Potential of neurotrophic factors in therapy of Parkinson's disease Journal of Neural Transmission. Supplementum 48: 103-112
Gehlen, W. 1980: Adverse effects of drug therapy in Parkinson disease Medizinische Monatsschrift für Pharmazeuten 3(4): 104-110
Horisberger, J.D. 2000: Placebo surgery in trials of therapy for Parkinson's disease New England Journal of Medicine 342(5): 354-355
Pfeiffer, C.; Wagner, M.L. 1994: Clozapine therapy for Parkinson's disease and other movement disorders American Journal of Hospital Pharmacy 51(24): 3047-3053
Mera, S.L. 1996: Parkinson's disease: prospects for prevention and improved therapy British Journal of Biomedical Science 53(3): 177-178
Slattery, J. 2000: Placebo surgery in trials of therapy for Parkinson's disease New England Journal of Medicine 342(5): 354; Author Reply 355
Pacchetti, C.; Aglieri, R.; Mancini, F.; Martignoni, E.; Nappi, G. 1998: Active music therapy and Parkinson's disease: methods Functional Neurology 13(1): 57-67
Kellner, C.H.; Beale, M.D.; Pritchett, J.T.; Bernstein, H.J.; Burns, C.M. 1994: Electroconvulsive therapy and Parkinson's disease: the case for further study Psychopharmacology Bulletin 30(3): 495-500
1997: Parkinson disease--planning of long-term therapy Der Nervenarzt 68(12 Suppl Morbus Par): 1-8
Muenter, M.D.; Sharpless, N.S.; Tyce, G.M. 1972: Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease Mayo Clinic Proceedings 47(6): 389-395
Petit, H. 1984: Early or late dopa therapy in Parkinson's disease Presse Medicale 13(36): 2213
Danielczyk, W. 1995: Twenty-five years of amantadine therapy in Parkinson's disease Journal of Neural Transmission. Supplementum 46: 399-405
Sale, P.; De Pandis, M.F.; Vimercati, S.L.; Sova, I.; Foti, C.; Tenore, N.; Fini, M.; Stocchi, F.; Albertini, G.; Franceschini, M.; Galli, M. 2013: The relation between Parkinson's disease and ageing. Comparison of the gait patterns of young Parkinson's disease subjects with healthy elderly subjects European Journal of Physical and Rehabilitation Medicine 49(2): 161-167
Calne, D.B.; Duvoisin, R.C.; Koller, W.C. 1994: Individualizing therapy in patients with disabling Parkinson's disease symptoms Neurology 44(3 Suppl 1: S8-11